Semaglutide 20mg | GLP-1 Economical Long-Cycle Format

Zoom

5mg29,00 €10mg49,00 €20mg83,00 €

83,00 €

Tax included • Free delivery from 99€

+4,15 € in loyalty cashback, with an account. Create my account

Only 5 left, flying off the shelf!

Next dispatch: Tuesday, September 8

What the parcel contains

One sealed vial of Semaglutide 20mg, lyophilised, without individual labelling.

What you also need

Bacteriostatic water for reconstitution and 1 ml precision syringes graduated in 100 units, sold separately. The vial alone cannot be used as is.

Don't forget the essentials

Eau Bactériostatique

7,90 €

Cartouches 3 mlx59,90 €

Aiguilles Stylo Injecteurx1010,90 €

Semaglutide 20mg is the economical long-cycle format of the GLP-1 range. Double dosage of the standard 10mg vial, it optimises mg/euro ratio for researchers conducting extended complete cycles (24-48 weeks) or multiple consecutive cycles without interruption. A single 20mg vial covers an integral STEP cycle at maximal dose (17 weeks titration + stable phase) with safety reserve, or two complete SUSTAIN cycles at 1 mg/week dose over 24 weeks. It's the format of choice for experienced researchers having already validated individual tolerance and optimal scheme.

Semaglutide remains, in 2025, the founding reference of the modern GLP-1 agonist class. Despite emergence of next-generation molecules (dual GLP-1/GIP tirzepatide, triple GLP-1/GIP/GCGR retatrutide) with superior metabolic amplitudes, semaglutide retains two decisive advantages: a massively superior clinical corpus (30+ phase III trials, 2M+ patient-years of pharmacovigilance) and a perfectly characterised tolerance profile over a decade. For research requiring reproducibility and comparison with existing literature, semaglutide remains unbeatable.

20mg vial use profiles: (1) Integral STEP cycle high doses: complete titration 0.25 -> 2.4 mg/week over 17 weeks + stable phase 8-12 weeks at 2.4 mg, total 30 weeks, cumulative consumption ~44 mg (requires 2 20mg vials). (2) Repeated SUSTAIN cycles at 1 mg/week: 24 weeks consume 24mg, about one 20mg vial + small supplement. (3) Extended maintenance protocols: after attack phase, maintenance at 0.5-1 mg/week for 6-12 months, one 20mg vial covers 6-12 months depending on dose.

Optimal reconstitution with 4ml USP bacteriostatic water giving 5 mg/ml, concentration readable for entire therapeutic range. More concentrated alternative 2ml giving 10 mg/ml (suited to high 2-5 mg doses per injection) or more dilute 5ml giving 4 mg/ml for titration micro-doses. Reconstitution volume choice depends on planned scheme - to define before opening the vial to avoid wasting solution on unsuitable volume.

Economic advantage: the 20mg vial typically offers a unit price 25-35% lower per mg than the 10mg vial, and 45-55% lower than the 5mg vial. For high-volume research, cost-usage ratio is unbeatable.

Science

01
Mechanism of action

Semaglutide is a complete and selective GLP-1 receptor agonist (Glucagon-Like Peptide-1 Receptor, GLP-1R), resulting from sophisticated molecular engineering carried out by Novo Nordisk on the native scaffold of endogenous human GLP-1. The base peptide is modified at three critical positions to simultaneously resolve the two major limitations of native GLP-1: plasma half-life of 1-2 minutes (rapid degradation by dipeptidyl peptidase-4, DPP-4) and weak albumin affinity compromising duration of action.

Semaglutide structural modifications (described by Lau et al 2015, J Med Chem):
1. Ala8 to Aib (alpha-aminoisobutyrate) substitution: totally blocks DPP-4 cleavage at the N-terminal site, primary cause of native GLP-1 inactivation.
2. Lys34 to Arg34 substitution: removes a potential glycation site and stabilises conformation.
3. Lys26 acylation with C18 diacid fatty chain (octadecanedioic acid) via glutamic linker: creates a highly lipophilic covalent anchor that reversibly binds to serum albumin.

This C18 diacid acylation is the heart of semaglutide's pharmacological innovation. Once subcutaneously injected and diffused into the vascular compartment, semaglutide binds mainly to serum albumin (> 99%) through hydrophobic interaction between the C18 chain and the albumin lipid pocket. This reversible binding serves as a plasma reservoir progressively releasing free peptide for action on GLP-1R. Result: plasma half-life of 155-180 hours (about one week), a 10,000-fold increase vs native GLP-1.

Cellular-level mechanism: once bound to GLP-1R (G-protein coupled receptor class B), semaglutide triggers a pleiotropic signalling cascade:
- Adenylate cyclase activation via Gs protein -> intracellular cAMP increase.
- PKA and EPAC2 activation -> potentiation of glucose-dependent insulin secretion by pancreatic beta cells (explaining the absence of iatrogenic hypoglycaemia except under concomitant insulin).
- Glucagon secretion inhibition by pancreatic alpha cells under hyperglycaemia (preserved in hypoglycaemia, counter-regulatory mechanism intact).
- Gastric emptying slowing via vagus nerve (central effect on dorsal vagal complex), prolonging satiety and flattening post-prandial glycaemic peaks.
- Central POMC neuron activation in hypothalamus (arcuate nucleus) and AgRP/NPY neuron inhibition -> drastic food intake and appetite reduction.
- Recently identified extra-metabolic effects: inflammatory modulation (CRP, TNF-alpha reduction), direct cardioprotective effects (experimental studies on cardiomyocytes), neuroprotective effects (studies on Alzheimer's and Parkinson's mouse models).

Semaglutide's GLP-1R selectivity distinguishes it from dual agonists (Tirzepatide GLP-1/GIP) or triple agonists (Retatrutide GLP-1/GIP/GCGR). This monospecificity offers a more predictable and better-characterised pharmacological profile (extensive clinical corpus SUSTAIN + STEP + SELECT), but limits metabolic amplitude vs more recent multi-receptor agonists. Semaglutide nevertheless remains the historical reference of the class and the best-documented GLP-1 molecule to date.

Clinical data

02Clinical studies

Semaglutide's clinical corpus is one of the most extensive of the entire modern peptide class, with more than 30 randomised controlled phase III trials published since 2016 and cumulative pharmacovigilance follow-up exceeding 2 million patient-years.

SUSTAIN program (type 2 diabetes, 8 main trials 2016-2020): evaluation of glycaemic efficacy and weight loss in type 2 diabetics.
- SUSTAIN-1 (Sorli et al 2017, Lancet Diabetes Endocrinol): HbA1c reduction -1.45% vs placebo over 30 weeks at 1mg/week dose.
- SUSTAIN-6 (Marso et al 2016, NEJM): major cardiovascular trial on 3297 high CV risk patients, significant reduction in composite CV mortality / non-fatal MI / non-fatal stroke endpoint (-26%, p=0.02), establishing semaglutide's cardiovascular benefit.
- SUSTAIN-7 (Pratley et al 2018, Lancet Diabetes Endocrinol): head-to-head comparison semaglutide 1mg vs dulaglutide 1.5mg, semaglutide superiority on HbA1c (-1.8% vs -1.4%) and weight (-6.5kg vs -3.0kg).

STEP program (non-diabetic obesity, 8 trials 2021-2023): weight loss evaluation at 2.4mg/week dose (obesity dose, higher than diabetes dose).
- STEP-1 (Wilding et al 2021, NEJM): flagship trial on 1961 non-diabetic overweight or obese adults, mean weight loss of -14.9% at 68 weeks (vs -2.4% placebo), -15% threshold reached in 50.5% of patients. Marking the greatest pharmacological anti-obesity advance since amphetamine derivatives of the 1970s.
- STEP-4 (Rubino et al 2021, JAMA): treatment cessation effect - mean weight regain of +6.9% over 48 post-cessation weeks, confirming the chronic nature required of treatment.
- STEP-5 (Garvey et al 2022, Nat Med): 2-year weight loss maintenance under continuous treatment, no early plateau, total mean loss -15.2%.

SELECT 2023 (Lincoff et al 2023, NEJM): major cardiovascular trial on 17,604 adults with established cardiovascular disease but without diabetes, randomised semaglutide 2.4mg vs placebo, mean 39.8 month follow-up. -20% reduction in primary composite endpoint (CV mortality, MI, stroke, p<0.001), demonstrating for the first time a GLP-1 cardiovascular benefit in secondary prevention in non-diabetics. Opening the way to a dedicated cardiovascular indication, distinct from the metabolic indication.

Detailed pharmacokinetics (Kapitza et al 2015, J Clin Pharmacol; Granhall et al 2019, Clin Pharmacokinet):
- SC bioavailability: 89%
- Tmax: 1-3 days after SC injection
- Distribution volume: 12.5 L
- Plasma protein binding: > 99% (mainly albumin)
- Half-life: 155-180 hours (7-8 days)
- Clearance: 0.05 L/h
- Metabolism: hepatic and renal proteolysis (comparable elimination to native GLP-1 once released from albumin)
- Excretion: 70% urinary, 30% faecal

Tolerance and adverse effects: cumulative SUSTAIN + STEP + SELECT data establish a well-characterised tolerance profile, dominated by digestive effects (nausea 15-44%, vomiting 5-25%, diarrhoea 15-30%, constipation 5-15%), generally transient during titration. Rare but serious effects: acute pancreatitis (< 0.5%), aggravated diabetic retinopathy in poorly controlled patients (SUSTAIN-6 weak signal), theoretical risk of medullary thyroid tumours (rodent signal unconfirmed in humans).

Post-marketing data 2022-2025: emergence of signals on concomitant muscle mass loss (up to 25% of weight loss is lean mass, Heymsfield 2023), persistent gastroparesis post-cessation in a few published cases, and glucagon-mediated peak recovery after abrupt cessation (rebound dumping). These observations reinforce the need for nutritional-muscular support and progressive cessation.

No references yet for this peptide — search PubMed for associated scientific literature.

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

Semaglutide 20mg reconstitution: three options depending on planned scheme.

Option A — 4ml USP bacteriostatic water (concentration 5 mg/ml, recommended for complete cycle):
- 2U = 0.02ml = 100 mcg — micro-test
- 5U = 0.05ml = 250 mcg — initial titration
- 20U = 0.2ml = 1000 mcg (1 mg) — SUSTAIN standard
- 48U = 0.48ml = 2400 mcg (2.4 mg) — Wegovy maximal
- Complete cycle 20mg / 4ml = 400U total aspirable.

Option B — 2ml USP bacteriostatic water (concentration 10 mg/ml, high doses only):
- 1U = 0.01ml = 100 mcg — very precise reading required
- 10U = 0.1ml = 1000 mcg (1 mg)
- 24U = 0.24ml = 2400 mcg (2.4 mg)
- 50U = 0.5ml = 5000 mcg (5 mg) — occasional high dose
- Suited to low injection frequency protocols and consolidation high doses.

Option C — 5ml USP bacteriostatic water (concentration 4 mg/ml, very progressive titration):
- 6U = 0.06ml = 250 mcg
- 25U = 0.25ml = 1000 mcg
- 60U = 0.6ml = 2400 mcg
- Ideally for ultra-progressive titration 0.05 mg -> 2.4 mg in micro-steps.

Long integral STEP cycle scheme (20 weeks titration + 20 weeks stable = 40 weeks, reconstitute in 4ml/5 mg/ml):
- Weeks 1-4: 0.25 mg (5U)
- Weeks 5-8: 0.5 mg (10U)
- Weeks 9-12: 1.0 mg (20U)
- Weeks 13-16: 1.7 mg (34U)
- Weeks 17-20: 2.4 mg (48U) — target dose reached
- Weeks 21-40: 2.4 mg (48U) — stable phase
- Cumulative consumption: 0.25×4 + 0.5×4 + 1×4 + 1.7×4 + 2.4×24 = 73 mg over 40 weeks — requires 2 20mg vials + 1 partial 20mg vial (73mg/40mg = 1.83 20mg vials, rounded to 2).

Repeated SUSTAIN cycle scheme: 24 weeks at 1 mg/week = 24 mg, one 20mg vial + 4 mg supplement (5mg or half a 10mg).

Extended maintenance scheme after initial loss: 0.5 mg/week dose for 6 months = 13 mg, 20mg vial covers 9 months of maintenance without supplement.

Technical 20mg vial opened storage management: with 4ml reconstituted solution, pharmacological shelf-life is 21-28 days at 2-8°C. For long cycles, 4ml reconstitution covers 3-4 weekly injections i.e. about 3 weeks of use. End-of-period residue must be discarded if duration exceeds 28 days, even if remaining volume is substantial. To optimise, split the vial: initially reconstitute 2ml, aspirate, re-add 2ml at D21 for 3 additional weeks ("two-step reconstitution" technique).

Economic-fiscal advantage: the 20mg vial is best quality-price ratio on usage range exceeding 10 cycle weeks. Below that, 10mg remains more relevant to avoid wasting expired peptide-solution residue.

Reconstitution for this format (20 mg)Standard volumes used in laboratory settings

Water added	Concentration	Reading marker
2 ml	10 mg/ml	10 UI = 1 mg
4 ml	5 mg/ml	40 UI = 2 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
The vial carries no individual label. That is our standard packaging, not a downgraded vial.
After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

Lyophilised semaglutide stores for 24 months in sealed vial at room temperature (15-25°C) protected from direct light. No pre-reconstitution refrigeration required. After reconstitution in USP bacteriostatic water, the solution peptide stores for 21-28 days at 2-8°C, beyond progressive chemical degradation by peptide hydrolysis measurable by HPLC.

Fragile chemical structure: despite stabilisation modifications (Aib8, Arg34, C18 diacid), semaglutide remains a long peptide (30 amino acids) with sensitivity sites:
- N-terminal amide bond: sensitive to acid or enzymatic hydrolysis.
- Methionine residue Met14: oxidation to methionine sulphoxide under prolonged dissolved oxygen exposure.
- Glutamic linker ester bond: possible hydrolysis in acidic solution (pH < 5).
- C18 acylated chain: chemically stable but can undergo progressive beta-oxidation over several weeks.

Optimal storage conditions:
- Unopened vial: 15-25°C, original cardboard packaging, protected from light, humidity < 60%.
- Opened reconstituted vial: strict 2-8°C, vertical position, vial covered or in cardboard box for light protection, do not freeze.
- Transport: refrigerated isothermal pack 2-8°C on trips > 2 hours. Temperatures > 30°C accelerate peptide degradation in solution.

Errors to avoid:
- Freeze-thaw: freeze-thaw cycles form ice crystals denaturing peptide tertiary conformation, 20-40% activity loss per cycle.
- Direct solar exposure: Met14 methionine and acylated Lys26 are photodegradable, 1-2 hour direct sun exposure can reduce activity by 5-15%.
- Vigorous agitation: semaglutide forms reversible oligomers in solution (dimers and trimers via C18), mechanical agitation can favour irreversible insoluble aggregates.
- Mixing with other peptides in same vial: unpredictable interactions with pH / ionic strength / other lipophilic residues. One vial = one peptide.

Recommended reconstitution with USP bacteriostatic water 0.9% benzyl alcohol. Typical reconstitution volume depending on nominal dosage (detailed below in Protocols section). Reconstituted peptide presents a clear solution, possibly slightly opalescent after a few hours (reversible C18 micro-oligomer formation), colourless. Any yellow or brown colouration signals oxidation or contamination -> rejection.

Alteration visual indicators: solution that remains turbid, appearance of floating particles, formation of deposit at vial bottom, perceptible odour (normally odourless), swollen vial (possible suspect internal pressure). Faced with any of these signs, discard the vial and use a new one.

01What is the fundamental difference between semaglutide and natural GLP-1?

Natural GLP-1 has a 1-2 minute half-life, degraded almost instantly by plasma DPP-4 enzyme. Semaglutide carries three key modifications: Aib8 blocks DPP-4 cleavage, Arg34 stabilises conformation, and a C18 diacid acylated chain on Lys26 creates reversible binding to serum albumin. Result: 155-180 hour half-life (7-8 days), a 10,000-fold increase. This half-life enables single weekly injection vs practical impossibility with native GLP-1.

02Why does semaglutide cause such significant weight loss?

Multiple mechanisms. (1) Centrally, POMC hypothalamic neuron activation and AgRP/NPY neuron inhibition drastically reduce hunger and appetite. (2) Vagal slowing of gastric emptying prolongs post-prandial satiety. (3) Indirect metabolic improvement: glycaemic control reduces insulin peaks favouring adipose storage. The STEP-1 trial (Wilding 2021 NEJM) showed -14.9% mean weight loss at 68 weeks in non-diabetics, with 50.5% of patients reaching -15%. Recent data also suggest systemic anti-inflammatory effects contributing to adipose remodelling.

03Does semaglutide cause hypoglycaemia?

No in monotherapy in non-diabetics or non-insulinised type 2 diabetics. The mechanism of action is **glucose-dependent**: semaglutide potentiates insulin secretion only when glycaemia is elevated, and inhibits glucagon only in hyperglycaemia. In hypoglycaemia, physiological counter-regulation remains intact. Increased hypoglycaemia risk only in combination with insulin or sulphonylureas, which then requires dose reduction of these concomitant drugs.

04What's the difference between semaglutide, tirzepatide and retatrutide?

Three successive generations of GLP-1 agonists. **Semaglutide** (2017): mono-GLP-1R agonist, -15% weight loss STEP-1. **Tirzepatide** (2022, Mounjaro): GLP-1R + GIPR co-agonist, adds GIP thermogenic arm, -20.9% weight loss SURMOUNT-1. **Retatrutide** (phase III ongoing): GLP-1R + GIPR + GCGR triple agonist, adds glucagon arm (thermogenesis + lipid beta-oxidation), -24.2% weight loss phase II Jastreboff 2023. Increasing metabolic amplitude, decreasing clinical corpus. Semaglutide remains best documented to date.

05What are the most frequent semaglutide side effects?

Digestive effect dominance, generally transient during titration (first 4-8 weeks). Nausea 15-44%, vomiting 5-25%, diarrhoea 15-30%, constipation 5-15%. Headaches, fatigue, excessive satiety sensations. Rare but serious effects: acute pancreatitis < 0.5%, persistent post-cessation gastroparesis (published cases), aggravated diabetic retinopathy in poorly controlled patients. Theoretical medullary thyroid tumour risk (rodent signal, unconfirmed in humans). Most digestive effects reduce with progressive titration and dietary adaptation (frequent small meals, avoid fat and fast sugars).

06How is semaglutide stored?

Unopened lyophilised vial: 24 months at 15-25°C protected from light, original cardboard packaging. After reconstitution: 21-28 days at strict 2-8°C (refrigerator), vertical position, protect from light. Never freeze (freeze-thaw cycles denature the peptide, 20-40% activity loss per cycle). Visually inspect before each use: solution should be clear or slightly opalescent (normal reversible C18 micro-oligomer formation), without yellow or brown colouration. Any lasting turbidity, particle, deposit or colouration = vial rejection.

07Should semaglutide be stopped progressively?

Recommended. Abrupt GLP-1 cessation after prolonged use can trigger a **metabolic rebound phenomenon**: accelerated weight regain (STEP-4 documents +6.9% over 48 post-cessation weeks), rapid recovery of central orexigenic signals, re-centring of hypothalamic set-point. Recommended scheme: progressive reverse titration over 4-8 weeks, dose reduction in 25% steps, nutritional support and physical activity to preserve the new metabolic set-point. Abrupt cessation does not neutralise effects but rapidly redeploys them.

08Does semaglutide cause muscle mass loss?

Yes, partially. Heymsfield 2023 data and STEP secondary analyses show that about 25% of weight loss under semaglutide is lean mass (muscle + organs + bone). It's a phenomenon common to rapid weight loss interventions (hypocaloric diet, bariatric surgery). Compensatory strategies: high protein intake (1.6-2.2 g/kg/day), 2-3x/week resistance training, progressive titration. New muscle-preservation targeted peptides (bimagrumab, experimental myostatin inhibitors) are emerging to counter this effect.

Benchmark

Similar peptides

Semaglutide vs native human GLP-1: native GLP-1 has a half-life of 1-2 minutes, unusable in therapeutic practice. Semaglutide, through its three structural modifications, reaches a half-life of 155-180 hours, a 10,000-fold increase. First synthetic GLP-1s (exenatide 2005, liraglutide 2010) progressed along this gradient without ever approaching semaglutide which remains the current mono-agonist class plateau.

Semaglutide vs Liraglutide (Victoza, Saxenda): liraglutide has a 13-hour half-life requiring daily injection, vs semaglutide once weekly. Comparable weight loss SUSTAIN/STEP (semaglutide -15% vs liraglutide -8% at obesity dose). Liraglutide retains niche utility (sensitive digestive profile patients tolerating lower peaks better). Semaglutide dominates on nearly all clinical criteria: efficacy, convenience (weekly), cardiovascular data, long-term cumulative tolerance.

Semaglutide vs Dulaglutide (Trulicity): direct SUSTAIN-7 comparison (Pratley 2018 Lancet Diabetes Endocrinol) on 1201 patients: semaglutide 1mg superior to dulaglutide 1.5mg on HbA1c (-1.8% vs -1.4%) and weight loss (-6.5kg vs -3.0kg). Same injection frequency (weekly). Dulaglutide retains marginal digestive tolerance advantage. Semaglutide = first choice if main objective is weight + glycaemia.

Semaglutide vs Tirzepatide (Mounjaro, Zepbound): tirzepatide is a GLP-1/GIP dual agonist from the next generation (approved 2022). SURMOUNT-1 trial (Jastreboff 2022 NEJM): mean weight loss at 72 weeks -20.9% at 15mg (vs -14.9% semaglutide STEP-1 at 2.4mg). Direct comparison SURPASS-2 (Frias 2021 NEJM, diabetics) shows tirzepatide 15mg superior to semaglutide 1mg on HbA1c and weight. Tirzepatide is mechanically more powerful thanks to GIP co-activation adding a thermogenic arm. Semaglutide retains the advantage of massive clinical corpus (> 10x longer) and specific SELECT cardiovascular data.

Semaglutide vs Retatrutide: retatrutide is an even more recent GLP-1/GIP/GCGR triple agonist (phase III ongoing late 2024-2025). Published phase II data (Jastreboff 2023 NEJM) suggest -24.2% weight loss at 48 weeks at 12mg - the highest ever observed in a peptide trial. The additional glucagon arm activates thermogenesis and lipid beta-oxidation. Semaglutide will remain relevant for its known profile and lower cost but will probably be surpassed in amplitude by retatrutide.

Semaglutide vs bupropion/naltrexone, orlistat, phentermine: older obesity pharmacological treatments typically reach -3 to -8% weight loss, largely inferior to semaglutide's -15%. Less favourable tolerance profiles (psychiatric bupropion/naltrexone effects, orlistat steatorrhoea, phentermine dependence). GLP-1s have redefined the obesity therapeutic standard starting with STEP-1.

Semaglutide oral (Rybelsus) vs Semaglutide SC (Ozempic, Wegovy): oral version (Rybelsus, approved 2019) available in 3, 7, 14 mg daily with absorption assisted by salcaprozate (SNAC). Oral bioavailability 1%, efficacy inferior to SC (-3 to -5 kg vs -15 kg). Practical interest (needle phobia) but unfavourable cost-efficacy ratio. Weekly SC form remains gold standard for peptide research and real practice.

Full guide: Semaglutide — mechanism, studies, dose comparison

Metabolism

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents